Drug Discovery

As the life science industry faces increasing competition—as well as global regulatory and pricing pressures—outsourcing portions or all of manufacturing is becoming increasingly prevalent....

In this sponsored GENcast listen to a conversation with Dr. Klaus Lun, Executive Vice President of Life Science Business for Tecan, provide his perspective on global developments pertaining to COVID-19 and other timely topics.

Currently, almost 60 percent of drugs in development are being created by emerging biotech companies focused on therapies for niche diseases with small patient...

The biomanufacturing industry is currently undergoing a revolution in how it produces biopharmaceutical products. The driving force behind this paradigm shift is known as...

In this GENcast, our guest will tell us more about HTS using 3D cell models and why they are so crucial for current drug discovery projects. Moreover, he will provide scientific insight into the 3D cell panel screening service—called OncoSignature™—which uses a library of 200 cell lines grown in 3D spheroids to provide a better understanding of candidate cancer therapeutics.

Sponsor: Sartorius Stedim BiotechIn this GEN webinar, sponsored by Sartorius Stedim Biotech, we will hear how application of modern bottle and flask closure technologies in combination with machine automation can compress a cell expansion process map to bring about a low-risk, streamlined workflow with reduced operating costs.

Sponsor: Advanced Cell DiagnosticsIn this GEN webinar, sponsored by Lonza, we will examine initial strategies to optimize the amino acid sequence of biotherapeutic molecules, along with techniques to maximize product quality through expression vector design. One tool, GS piggyBac™, which can help improve expression levels, especially for more complex, next-generation biologics, will be discussed.

Sponsor: Iowa Economic Development AuthorityIn this GEN webinar, we will hear a series of presentations highlighting some of the high-quality bioscience research that is emerging from various industries across Iowa. Specifically, two of our presenters will discuss not only the manufacturing and testing capabilities to advance new vaccine candidates into clinical trials, but also some of the technological advances, facilities, and infrastructure that are being applied to pandemic preparedness and rapid vaccine development.

Eli Lilly will apply Dicerna Pharmaceuticals’ GalXC™ RNA interference (RNAi) technology platform to discover, develop, and commercialize new treatments based on more than 10...

Sponsor: SynthegoIn this on demand debut of “GEN Live”, Julianna LeMieux and Alex Philippidis discuss the latest medical advances in drug and vaccine development, as well as diagnostic and antibody testing. They go beyond the written word to share news and insights, ranking the frontrunner drug and vaccine candidates aiming to vanquish the virus. Attendees were able to ask questions live or via chat/social media.